• Media type: E-Article
  • Title: Changes in vitamin D and calcium metabolism markers in patients undergoing adjuvant chemotherapy for breast cancer
  • Contributor: Viala, Marie; Firmin, Nelly; Touraine, Célia; Pouderoux, Stéphane; Metge, Manon; Rifai, Lobna; Romieu, Gilles; de Forges, Hélène; Roca, Lise; Guiu, Séverine; D’Hondt, Véronique; Jacot, William
  • Published: Springer Science and Business Media LLC, 2021
  • Published in: BMC Cancer
  • Extent:
  • Language: English
  • DOI: 10.1186/s12885-021-08563-4
  • ISSN: 1471-2407
  • Keywords: Cancer Research ; Genetics ; Oncology
  • Abstract: <jats:title>Abstract</jats:title><jats:sec> <jats:title>Background</jats:title> <jats:p>Changes in calcium metabolism and calcium urinary excretion during chemotherapy have not been thoroughly assessed in patients with early breast cancer (EBC), a population who frequently present vitamin D insufficiency. As hypercalciuria is a classical contra-indication to vitamin D (VD) supplementation, this study evaluated changes in VD and calcium metabolism parameters in patients with EBC undergoing adjuvant chemotherapy (CT).</jats:p> </jats:sec><jats:sec> <jats:title>Methods</jats:title> <jats:p>In patients with EBC who received six cycles of adjuvant CT, VD and calcium parameters were monitored at inclusion, and then every 3 weeks, at each CT cycle initiation. The primary endpoint was the percentage of patients showing hypercalciuria during adjuvant CT (between Day 1, Cycle 1 [D1C1] and Day 1, Cycle 6 [D1C6]).</jats:p> </jats:sec><jats:sec> <jats:title>Results</jats:title> <jats:p>The primary endpoint could be evaluated in 82 patients. Most patients (<jats:italic>n</jats:italic> = 66, 80.5%) had VD insufficiency (&lt; 30 ng/mL) at baseline. Hypercalciuria was detected in 29 patients (35.4%; 95% CI: 25.6–46.5) between D1C1 and D1C6, but was not clinically significant in any of the affected patients. The percentage of hypercalciuria events was not different between patients with sufficient and insufficient baseline VD levels (34.8% vs. 37.5%), and between patients who received or not VD supplementation (37.5% vs. 34.5%,).</jats:p> </jats:sec><jats:sec> <jats:title>Conclusions</jats:title> <jats:p>This comprehensive study on VD and calcium parameter changes in patients with EBC during adjuvant chemotherapy shows that hypercalciuria is a frequent abnormality in this setting, although asymptomatic. Therefore, it should not be considered as a limitation for high dose VD supplementation in this population.</jats:p> </jats:sec><jats:sec> <jats:title>Trial registration</jats:title> <jats:p><jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://eudract.ema.europa.eu/EudraCT2014-A01454-43">EudraCT:2014-A01454-43</jats:ext-link>. Registered 29 august 2016.</jats:p> </jats:sec>
  • Description: <jats:title>Abstract</jats:title><jats:sec>
    <jats:title>Background</jats:title>
    <jats:p>Changes in calcium metabolism and calcium urinary excretion during chemotherapy have not been thoroughly assessed in patients with early breast cancer (EBC), a population who frequently present vitamin D insufficiency. As hypercalciuria is a classical contra-indication to vitamin D (VD) supplementation, this study evaluated changes in VD and calcium metabolism parameters in patients with EBC undergoing adjuvant chemotherapy (CT).</jats:p>
    </jats:sec><jats:sec>
    <jats:title>Methods</jats:title>
    <jats:p>In patients with EBC who received six cycles of adjuvant CT, VD and calcium parameters were monitored at inclusion, and then every 3 weeks, at each CT cycle initiation. The primary endpoint was the percentage of patients showing hypercalciuria during adjuvant CT (between Day 1, Cycle 1 [D1C1] and Day 1, Cycle 6 [D1C6]).</jats:p>
    </jats:sec><jats:sec>
    <jats:title>Results</jats:title>
    <jats:p>The primary endpoint could be evaluated in 82 patients. Most patients (<jats:italic>n</jats:italic> = 66, 80.5%) had VD insufficiency (&lt; 30 ng/mL) at baseline. Hypercalciuria was detected in 29 patients (35.4%; 95% CI: 25.6–46.5) between D1C1 and D1C6, but was not clinically significant in any of the affected patients. The percentage of hypercalciuria events was not different between patients with sufficient and insufficient baseline VD levels (34.8% vs. 37.5%), and between patients who received or not VD supplementation (37.5% vs. 34.5%,).</jats:p>
    </jats:sec><jats:sec>
    <jats:title>Conclusions</jats:title>
    <jats:p>This comprehensive study on VD and calcium parameter changes in patients with EBC during adjuvant chemotherapy shows that hypercalciuria is a frequent abnormality in this setting, although asymptomatic. Therefore, it should not be considered as a limitation for high dose VD supplementation in this population.</jats:p>
    </jats:sec><jats:sec>
    <jats:title>Trial registration</jats:title>
    <jats:p><jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://eudract.ema.europa.eu/EudraCT2014-A01454-43">EudraCT:2014-A01454-43</jats:ext-link>. Registered 29 august 2016.</jats:p>
    </jats:sec>
  • Footnote:
  • Access State: Open Access